Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medlive Technology CoFRA:1JZ +2.93%90 Return-on-Tangible-Asset is 7.36% as of Dec. 2025, which is 9% above its 10-year median of 6.78. GuruFocus rates FRA:1JZ with a GF Score™ of 90/100 and a GF Value™ of €1.61. The stock has 5 warning signs investors should review. Among 679 Healthcare Providers & Services companies, Medlive Technology Co ranks better than 70.4% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Medlive Technology Co's annualizedNet Income for the quarter that ended in Dec. 2025 was €43.41 Mil. Medlive Technology Co's average total tangible assets for the quarter that ended in Dec. 2025 was €589.39 Mil. Therefore, Medlive Technology Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 7.36%.
The historical rank and industry rank for Medlive Technology Co's Return-on-Tangible-Asset or its related term are showing as below:
FRA:1JZ'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.91 Med: 6.78 Max: 51.03
Current: 6.94
During the past 8 years, Medlive Technology Co's highest Return-on-Tangible-Asset was 51.03%. The lowest was 1.91%. And the median was 6.78%.
FRA:1JZ's Return-on-Tangible-Asset is ranked better than 70.4% of 679
companies
in the Healthcare Providers & Services industry
Industry Median: 2.51
vs FRA:1JZ: 6.94
Medlive Technology Co (FRA:1JZ) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Medlive Technology Co Return-on-Tangible-Asset Related Terms
Medlive Technology Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Medlive Technology Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medlive Technology Co Return-on-Tangible-Asset Chart
FRA:1JZ vs VEEV, BTSG, HQY: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, Medlive Technology Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medlive Technology Co Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medlive Technology Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Medlive Technology Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 7.36% mean?
Medlive Technology Co (FRA:1JZ) has a Return-on-Tangible-Asset of 7.36% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Medlive Technology Co and its competitors. This is near median its historical median of 6.78. Over the past decade, Medlive Technology Co's Return-on-Tangible-Asset has ranged from 1.91 to 51.03. According to the industry distribution chart, Medlive Technology Co ranks #201 out of 679 companies in the Healthcare Providers & Services industry, placing it in the top 29.6%.
Is Medlive Technology Co's Return-on-Tangible-Asset too high?
Medlive Technology Co's current Return-on-Tangible-Asset of 7.36% is near median its 10-year median of 6.78. Over the past 10 years, this metric has ranged from a low of 1.91 to a high of 51.03. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.51. Medlive Technology Co's value of 7.36% is 193.2% above this industry median. Based on the distribution chart, Medlive Technology Co ranks #201 out of 679 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Medlive Technology Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Medlive Technology Co's Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Medlive Technology Co ranks #201 out of 679 companies for Return-on-Tangible-Asset. This puts Medlive Technology Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.51. Medlive Technology Co's value of 7.36% is 193.2% above this benchmark. Historically, Medlive Technology Co's own Return-on-Tangible-Asset has ranged from 1.91 to 51.03 over the past decade. While the company's 10-year median is 6.78 vs. the industry median of 2.51, Medlive Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.51, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medlive Technology Co's current Return-on-Tangible-Asset of 7.36% is 193.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Medlive Technology Co and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medlive Technology Co's current Return-on-Tangible-Asset is 7.36%, which is near median its own 10-year median of 6.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medlive Technology Co stock overvalued right now?
Medlive Technology Co (FRA:1JZ) has a current Return-on-Tangible-Asset of 7.36%. The stock's GF Value™ is €1.61, compared to a current price of €0.84 — trading 47.6% below its estimated fair value. The current Return-on-Tangible-Asset is 7.36%, which is near median its 10-year median of 6.78 and 193.2% above the Healthcare Providers & Services industry median of 2.51. Medlive Technology Co's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Medlive Technology Co (FRA:1JZ), the current Return-on-Tangible-Asset is 7.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medlive Technology Co (FRA:1JZ) Overvalued in 2026?
Based on GuruFocus' analysis, Medlive Technology Co stock appears to be undervalued.
The current stock price of €0.84 is trading 47.6% below its estimated GF Value™ of €1.61.
Key valuation signals for FRA:1JZ:
Return-on-Tangible-Asset: 7.36% (near median its 10-year median of 6.78)
GF Value™: €1.61 vs. price of €0.84 (47.6% below fair value)
Industry Position: 193.2% above the Healthcare Providers & Services median (#201 of 679)
No single metric tells the full story. See the FRA:1JZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medlive Technology Co Ltd is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms. The company developed into a professional provider of medical information services and precision digital marketing services. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and a SaaS solution that helps with medical conferences and clinical research.
90GF Score
Get the complete analysis for FRA:1JZ
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1JZ has been successfully added to your 
